Raylumis (tanezumab)
- Region
- 🇪🇺 EU
- Active substance
- tanezumab
- Company
- Pfizer Europe MA EEIG
- Status
- Refused
- Therapeutic area
- Osteoarthritis; Pain
- CHMP opinion
- Thu 16 Sep 2021
- Application
- EMEA/H/C/005189
- ATC
- N02
- Official record
- www.ema.europa.eu
Indication
Treatment of moderate to severe chronic pain associated with osteoarthritis (OA) of the hip or knee in adult patients for whom treatment with non-steroidal anti-inflammatory drugs (NSAIDs) and/or any opioid is ineffective, not tolerated or inappropriate.
Regulatory milestones
No milestones recorded in the last year.
Follow Raylumis
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.